- House overwhelmingly approves $16 billion cash infusion for VA overhaul
- Obama admin to blame for HealthCare.gov woes, $840M cost: GAO
- Al Gore’s climate-changers at EPA hearings foiled by cool temperatures
- Army’s 3-D printed bombs will create ‘a whole new universe’ of deadly capabilities
- Hamas calls on Hezbollah to join in fight against Israel
- Senators to FIFA, others: Don’t reward Putin with the World Cup in 2018
- U.S. condemns shelling of U.N. school in Gaza
- Obamacare shoots premiums up by 88 percent in California
- Chicken pox outbreak puts illegal immigrant facility on lockdown
- Obama to Republicans: ‘Stop just hatin’ all the time’
By Ted Cruz
Israel saves its enemies; Hamas endangers its friends
Topic - Sac Capital
The former SAC Capital Advisors portfolio manager was convicted Thursday of helping his company earn more than a quarter billion dollars illegally through trades based on secrets about the testing of a potential breakthrough Alzheimer's drug.
A former SAC Capital Advisors portfolio manager was convicted Thursday of helping the company owned by billionaire Steven A. Cohen earn more than a quarter-billion dollars illegally through trades based on secrets about the testing of a potential breakthrough Alzheimer's drug.
An "avalanche of evidence" points to the guilt of a former SAC Capital Advisors hedge fund portfolio manager charged with using inside information to earn his company over a quarter of a billion dollars, a prosecutor told a jury Monday.
An Alzheimer's expert testified Tuesday that he was too ashamed to be truthful when the FBI confronted him with claims he fed inside information to a hedge fund manager whose company owned pharmaceutical stocks.
A doctor testifying at an insider trading trial told a jury on Tuesday that he revealed secrets about the testing of a drug to treat Alzheimer's disease to a large hedge fund's money manager, who paid him $1,500 an hour for consultations.
NEW YORK (AP) — A former SAC Capital Advisors portfolio manager got inside information about an Alzheimer's drug trial and made a pivotal phone call to his billionaire boss a day before the hedge fund began dumping more than $700 million in pharmaceutical stocks, a prosecutor told a jury Friday in opening statements at the trader's criminal trial.
A former hedge fund portfolio manager accused of enabling a quarter of a billion dollars in profits by passing along inside information in one of the largest insider trading fraud cases in history appeared in a Manhattan court for the first time Monday and was released on $5 million bail, though his movements were restricted.
A former hedge fund portfolio manager was arrested Tuesday in what prosecutors called perhaps the most lucrative insider trading scheme of all time _ an arrangement to obtain secret, advance results of tests on an experimental Alzheimer's drug that netted more than $276 million for his fund and others.